Examining the clinical profile of nelotanserin, a novel agent in development for Lewy body dementia
Objective: To examine the clinical profile of nelotanserin, a novel agent in development for the treatment of Lewy body dementia. Background: Although not FDA-approved for…Dementia in Parkinson’s disease is associated with increased diffusivity in amygdala and external capsule
Objective: To identify which regions are associated with dementia in Parkinson's disease (PD) brains. Background: Dementia is common in advanced PD and its early development…Chronic cerebral hypoperfusion accelerates cognitive dysfunction and microvascular impairment in the MPTP mouse model of Parkinson’s disease
Objective: To evaluate cerebral hypoperfusion on cognitive dysfunction and related microvascular impairment in the MPTP mouse model. Background: Vascular pathology and Parkinson's disease (PD) pathology…FYN expression is associated with regulatory region genetic variation
Objective: The hypothesis of this investigation was that FYN expression and promoter activity are significantly influenced according to genetic content. The objective of this investigation…Visual hallucinations may serve as a possible predictor for Parkinson’s disease dementia
Objective: To observe whether visual hallucinations serve as a predictor of Parkinson's disease dementia. Background: Visual hallucinations (VH) is one of non-motor symptoms in Parkinson's…Combinative therapy of memantine and galantamine hydrobromide as a tool of choice for the treatment of vascular parkinsonism with early appearance of dementia symptoms
Objective: Our primary aim was comparative study of monotherapy with memantine and combinative therapy with memantine and galantamine hydrobromide for treatment of vascular parkinsonism with…Cognitive profile in the Parkinsonian variant of multiple system atrophy: Findings from a Tunisian cohort
Objective: To establish the cognitive profile of MSA-P in a Tunisian cohort and to discuss its association with motor signs. Background: It has been previously…Association of Parkinson’s disease severity and cortical and subcortical cognitive markers
Objective: To assess cortical and subcortical dysfunction in several stages of Parkinson's disease (PD) using the Parkinson's disease-cognitive rating scale (PD-CRS). Background: Cognitive impairment in…The evaluation of metabolic differences by using 18F-FDG-PET/CT in demented and non demented Idiophatic Parkinson’s disease patients
Objective: The objective of this study was to identify metabolic group differences between Idiopatic Parkinson's disease patients with dementia (PDD) and without dementia (PD), by…Single-subject FDG PET patterns and cognitive dysfunctions in Parkinson’s disease
Objective: To evaluate [18]FDG-PET single-subject perfusion patterns in Parkinson's disease (PD) patients and their relationship with cognitive dysfunction and progression during five years of follow-up.…
- « Previous Page
- 1
- …
- 31
- 32
- 33
- 34
- 35
- 36
- Next Page »